/ Marksans Pharma Q4FY17 Standalone Net Profit Declines 88.8% Yoy ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 29 May 2017

Marksans Pharma standalone revenue for the quarter came in at Rs. 54 crore, registering 21.7% yoy decline. EBITDA for the quarter fell by 42.9% yoy to Rs. 4 crore with a corresponding margin contraction of 273 bps. EBITDA margin for the quarter stood at 7.4%. This margin contraction was driven by 19% yoy increase in employee benefit expenses.

The PAT for the quarter came in at Rs. 0.57 crore, yoy decline of 88.8%. This was backd by 31% yoy increase in finance cost.

Looking at the full year numbers, we see that revenue slided by 40% to reach Rs.215.84 crore while EBITDA fell by 77% to 24.27 crore. Company reported net profit of Rs.12.22 crore, down 83% yoy. The board has recommended dividend of Rs. 0.05 per share for the face value of Rs. 1 each.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔